Savara SVRA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Innoviva, Inc.INVA

$11.2M+465%

XER

Xeris Biopharma Holdings, Inc.XERS

$36.85M-4.5%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

Upstream Bio, Inc.UPB

$1.27M-30.8%

MannkindMNKD

$11.76M-7.5%

4D Molecular TherapeuticsFDMT

$20.54M-13.9%

FAQ

What is Savara's operating lease liabilities (total)?

Savara (SVRA) reported operating lease liabilities (total) of $1.09M in Q2 2026.

What is the long-term trend for Savara's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Savara's operating lease liabilities (total) has grown at a -19.6% compound annual growth rate (CAGR), from $253K to $85K.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.